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Résumé en
anglais
Frontotemporal dementia (FTD) is a fatal neurodegenerative disease characterized by
behavioral and language disorders. The main genetic cause of FTD is an intronic
hexanucleotide repeat expansion (G4C2)n in the C9ORF72 gene. A loss of function of
the C9ORF72 protein associated with the allele-specific reduction of C9ORF72
expression is postulated to contribute to the disease pathogenesis. To better
understand the contribution of the loss of function to the disease mechanism, we need
to determine precisely the level of reduction in C9ORF72 long and short isoforms in
brain tissue from patients with C9ORF72 mutations. In this study, we developed a
sensitive and robust mass spectrometry (MS) method for quantifying C9ORF72
isoform levels in human brain tissue without requiring antibody or affinity reagent. An
optimized workflow based on surfactant-aided protein extraction and pellet digestion
was established for optimal recovery of the two isoforms in brain samples. Signature
peptides, common or specific to the isoforms, were targeted in brain extracts by
multiplex MS through the parallel reaction monitoring mode on a
Quadrupole–Orbitrap high resolution mass spectrometer. The assay was successfully
validated and subsequently applied to frontal cortex brain samples from a cohort of
FTD patients with C9ORF72 mutations and neurologically normal controls without
mutations. We showed that the C9ORF72 short isoform in the frontal cortices is below
detection threshold in all tested individuals and the C9ORF72 long isoform is
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